Steigerwald Gordon & Koch Inc. Has $455,000 Position in Merck & Co., Inc. (NYSE:MRK)

Steigerwald Gordon & Koch Inc. boosted its stake in shares of Merck & Co., Inc. (NYSE:MRKGet Rating) by 19.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 4,989 shares of the company’s stock after buying an additional 823 shares during the quarter. Steigerwald Gordon & Koch Inc.’s holdings in Merck & Co., Inc. were worth $455,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of MRK. Joseph P. Lucia & Associates LLC acquired a new position in shares of Merck & Co., Inc. in the 1st quarter valued at about $25,000. Landmark Wealth Management LLC acquired a new position in shares of Merck & Co., Inc. in the 1st quarter valued at about $25,000. Front Row Advisors LLC lifted its stake in shares of Merck & Co., Inc. by 89.4% in the 4th quarter. Front Row Advisors LLC now owns 339 shares of the company’s stock valued at $26,000 after purchasing an additional 160 shares during the period. Okabena Investment Services Inc. acquired a new position in shares of Merck & Co., Inc. in the 4th quarter valued at about $27,000. Finally, Western Pacific Wealth Management LP acquired a new position in shares of Merck & Co., Inc. in the 4th quarter valued at about $29,000. 73.33% of the stock is owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Performance

MRK stock opened at $87.51 on Friday. Merck & Co., Inc. has a 12-month low of $71.50 and a 12-month high of $95.72. The company has a quick ratio of 1.15, a current ratio of 1.39 and a debt-to-equity ratio of 0.66. The business has a 50 day moving average of $88.83 and a 200-day moving average of $87.81. The firm has a market cap of $221.69 billion, a PE ratio of 13.40, a P/E/G ratio of 1.14 and a beta of 0.33.

Merck & Co., Inc. (NYSE:MRKGet Rating) last posted its quarterly earnings data on Thursday, July 28th. The company reported $1.87 EPS for the quarter, beating the consensus estimate of $1.67 by $0.20. Merck & Co., Inc. had a return on equity of 48.45% and a net margin of 29.00%. The business had revenue of $14.59 billion for the quarter, compared to the consensus estimate of $13.85 billion. During the same quarter in the prior year, the business earned $1.31 earnings per share. Merck & Co., Inc.’s revenue for the quarter was up 28.0% on a year-over-year basis. As a group, sell-side analysts expect that Merck & Co., Inc. will post 7.33 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 15th will be paid a $0.69 dividend. The ex-dividend date of this dividend is Wednesday, September 14th. This represents a $2.76 annualized dividend and a yield of 3.15%. Merck & Co., Inc.’s payout ratio is 42.27%.

Analyst Ratings Changes

A number of analysts recently commented on the company. Erste Group Bank raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Thursday, August 25th. Morgan Stanley boosted their target price on Merck & Co., Inc. from $88.00 to $92.00 and gave the company an “equal weight” rating in a research report on Friday, July 29th. UBS Group boosted their target price on Merck & Co., Inc. from $76.00 to $98.00 and gave the company a “neutral” rating in a research report on Monday, July 18th. Mizuho assumed coverage on Merck & Co., Inc. in a research report on Friday, June 24th. They issued a “buy” rating and a $100.00 target price for the company. Finally, SVB Leerink boosted their target price on Merck & Co., Inc. from $105.00 to $109.00 and gave the company an “outperform” rating in a research report on Monday, September 12th. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $98.28.

Merck & Co., Inc. Profile

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Featured Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.